Bioanalysis in the Age of New Drug Modalities

Area of Science:

• Pharmacology and Pharmaceutical Sciences
• Biotechnology
• Analytical Chemistry

Background:

• Emerging drug modalities, including RNA-based therapeutics, bispecific antibodies, and gene/cell therapies, present unique bioanalytical challenges.
• The absence of specific regulatory guidelines necessitates tailored bioanalytical strategies for these complex molecules.
• Characterizing intact drugs, functional domains, biotransformation, and immunogenicity is crucial for novel therapeutics.

Purpose of the Study:

• To review the bioanalytical challenges and considerations for various complex drug modalities.
• To discuss a range of bioanalytical methods applicable to these novel therapeutics.
• To propose best practices for method selection, validation, and future perspectives in the field.

Main Methods:

• Review of existing literature and established bioanalytical techniques.
• Discussion of methods such as ligand binding assays (LBAs), liquid chromatography-mass spectrometry (LC-MS).
• Exploration of techniques like quantitative polymerase chain reaction (qPCR) and flow cytometry for specific modalities.

Main Results:

• Identification of key bioanalytical challenges associated with RNA-based drugs, bispecific antibodies, multi-domain proteins, prodrugs, gene/cell therapies, and fusion proteins.
• Comparison of the suitability of different bioanalytical methods for diverse drug modalities.
• Proposal of best practices for method selection and validation tailored to complex therapeutics.

Conclusions:

• Standardized bioanalytical strategies are essential for the development and regulatory approval of novel drug modalities.
• A combination of conventional and specialized bioanalytical methods is often required.
• Continued research and collaboration are needed to establish robust bioanalytical frameworks for future drug development.